Eko Analysis Software vs EchoNext
AI Verdict
Choose Eko Analysis Software if…
Choose Eko Analysis Software if you need a portable, point-of-care solution for early detection of common cardiovascular conditions during routine physical exams. It's ideal for clinicians who want to augment their auscultation skills with AI-powered heart murmur and AFib detection, visualize phonocardiograms and ECGs, and securely store recordings for patient monitoring and telehealth.
View Eko Analysis Software →Choose EchoNext if…
Choose EchoNext if you require a sophisticated, non-invasive AI tool for analyzing standard 12-lead ECGs to uncover hidden structural heart diseases like heart failure, valve disease, and pulmonary hypertension. This tool is best suited for practices and hospitals seeking to enhance their diagnostic capabilities for complex cardiac conditions and identify patients who may need further evaluation with echocardiography.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Eko Analysis Software | EchoNext |
|---|---|---|
| Pricing | Freemium with subscription for full features | Starts at $600/month |
| Deployment | Cloud-based | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Eko Analysis SoftwareEko Analysis Software integrates with Eko's digital stethoscopes and mobile app, offering wireless auscultation, recording, playback, and visualization of heart sounds and ECGs, suggesting a streamlined and integrated user experience at the point of care. The Eko App also provides step-by-step guidance for exams and automatic record-keeping. EchoNext, while offering powerful diagnostic capabilities, is deployed through the OpenEvidence clinical decision support platform, which may introduce an additional layer of complexity or require users to adapt to an existing platform's interface.
Clinical Value
EchoNextEchoNext analyzes standard ECGs to detect a broader range of hidden structural heart diseases, including heart failure, valve disease, and pulmonary hypertension, and has demonstrated superior accuracy compared to cardiologists in studies. Eko Analysis Software focuses on the early detection of heart murmurs and atrial fibrillation. While both are FDA-cleared and clinically valuable, EchoNext's ability to identify a wider spectrum of often-missed structural heart conditions from a routine ECG offers a potentially higher clinical impact for early intervention.
Pricing & Value
Eko Analysis SoftwareEko Analysis Software offers a freemium model with a subscription for full features, including a complimentary trial period, which allows users to experience the basic functionalities before committing financially. EchoNext has a starting price of $600/month, with tiered pricing and an implementation fee, which may represent a higher initial barrier to adoption, especially for smaller practices.
Enterprise Readiness
EchoNextEchoNext is designed for broad access, from major hospitals to community practices, and is deployed through the OpenEvidence clinical decision support platform, which is used by 650,000 U.S. physicians. This wide deployment and integration with an established platform suggest strong enterprise readiness. Eko Analysis Software is marketed as an enterprise solution with a focus on hospitals, health systems, and integrated delivery networks, and offers secure cloud-based storage and HIPAA compliance, but its integration with a broader clinical decision support ecosystem is not as explicitly stated.
Innovation
EchoNextEchoNext represents a significant innovation by utilizing standard ECGs to detect a wide range of hidden structural heart diseases, a capability previously not achievable with ECGs alone. This approach addresses a critical gap in early detection for conditions often missed until symptomatic. Eko Analysis Software, while innovative in its integration with digital stethoscopes and AI for murmur and AFib detection, builds upon existing auscultation methods.
Support & Docs
TieBoth tools are FDA-cleared and HIPAA compliant, implying a level of rigor in their development and a commitment to providing necessary documentation. Eko provides user manuals, FAQs, and direct contact support. EchoNext, being deployed through OpenEvidence, likely benefits from the support and documentation infrastructure of that platform, but specific details on its direct support and documentation are not as readily available.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Eko Analysis Software | EchoNext |
|---|---|---|
| Tool Name | Eko Analysis Software | EchoNext |
| Company | Eko Devices | Pathway Labs |
| Description | FDA-cleared AI-powered tool that integrates with Eko's digital stethoscopes and mobile app to assist clinicians in the early detection of cardiovascular diseases like heart murmurs and atrial fibrillation. | FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Detections | FDA-cleared AI for heart murmur detection, FDA-cleared AI for atrial fibrillation (AFib) detection, Detection of normal sinus rhythm | Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators |
| Input Data Type | Heart sounds and ECGs (via digital stethoscopes) | Standard 12-lead ECGs |
| Specialties | Cardiology, Emergency Medicine, Internal Medicine | Cardiology, Family Medicine, Hospital Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring Eko Analysis Software and EchoNext.